Director of Underwriting
Phil started his insurance career in 2000. In 2004 Phil moved to QBE to take up a role as pharmaceutical underwriter within the company operations. The role expanded over the next 10 years, initially into medical malpractice and management of the medical liability portfolio and then additionally into the International liability space where he was responsible for the Canadian liability portfolio. Phil established MCI in 2014.
Phil previously worked for Barbican’s Lloyds Syndicate 1955 where he was responsible for the oversight of MCI.
Anthony is responsible for the General Liability portfolio at MCI on a worldwide excluding USA basis.
In 2000, Anthony began his career at Willis and in 2005 joined QBE to work as an Underwriter within the recently formed Medical Liability team. Anthony initially worked on Clinical Trials and Pharmaceutical accounts before later being involved in the Medical Malpractice book prior to transferring into the General Liability team. During his 10 year career at QBE, Anthony was promoted to Senior Underwriter then Underwriting Manager and worked across a number of different portfolios also including the product recall/guarantee book.
Dan is responsible for the pharmaceutical and clinical trials portfolio at MCI.
In 2000, Dan began his career at Aon in London, and moved to Paragon in 2004. In 2007 Dan joined QBE to work as an Underwriter within the Medical liability team where he was responsible for the day to day underwriting of the Pharmaceutical, Medical Device, and Clinical Trials account on a global basis. Dan was promoted to Portfolio Manager of the Medical Liability account in 2014 where his responsibility was further extended to the Medical Malpractice account.
James is responsible for the medical malpractice portfolio at MCI.
James started his insurance career in 2010 at Lloyd’s of London and in 2011 moved to QBE to work as an Underwriter within the Medical Liability team where he was responsible for the day to day underwriting of medical malpractice, clinical trials and pharmaceutical liability. In 2014 James became responsible for the medical malpractice portfolio.